GLP-1 Over the Counter: Prescription vs Compounded Options

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medications cannot be legally purchased over the counter in the United States—they are controlled prescription drugs requiring medical evaluation and ongoing monitoring. The FDA restricts GLP-1 agonists (semaglutide, tirzepatide, retatrutide) to prescription status because metabolic pathways, kidney function, thyroid history, and cardiovascular factors must be assessed before initiation.

Understanding why GLP-1s require prescriptions, not OTC status, is crucial for safe, effective use. PlexusDx emphasizes precision-wellness: genetic and biomarker context can inform provider discussions about candidacy, dosing strategy, and potential metabolic responses—helping patients make informed decisions with their healthcare team.

Why GLP-1 Medications Remain Prescription-Only

GLP-1 agonists are prescription drugs because they affect multiple organ systems: pancreatic insulin secretion, gastric motility, appetite signaling, and cardiovascular hemodynamics. Clinical trials and post-market surveillance revealed risks in specific populations (history of medullary thyroid cancer, pancreatitis, severe kidney disease) that require pre-treatment screening unavailable in OTC settings.

Regulatory frameworks—FDA approval pathways, DEA scheduling considerations, and pharmacist oversight—exist to ensure medications are prescribed by licensed providers who can assess individual risk factors, perform baseline labs, and titrate dosing safely over months. OTC status would eliminate this critical accountability layer.

Prescription GLP-1 Access Pathways: Branded vs. Compounded

Two main pathways exist for prescription GLP-1 access: FDA-approved branded drugs (Ozempic, Wegovy, Mounjaro, Zepbound) dispensed by retail/mail-order pharmacies, and compounded semaglutide and tirzepatide from licensed 503A compounding pharmacies. Both require prescriptions; differences lie in manufacturing oversight, cost, and ingredient formulation.

Compounded GLP-1 medications sourced from 503A licensed pharmacies offer lower-cost alternatives ($129–$309/month depending on protocol) and may provide flexibility in dosing or delivery method. Branded options typically cost $900–$1,500/month before insurance. Provider preference, insurance coverage, and individual metabolic factors guide which pathway suits each patient.

Access Factor	FDA-Approved Branded	Compounded (503A)
Regulatory pathway	Full FDA approval; single-source manufacturer	Licensed pharmacy compounding; state board oversight
Typical monthly cost	$900–$1,500 (before insurance)	$129–$309 depending on protocol
Dosing flexibility	Fixed pen strengths; limited customization	Can adjust concentrations per provider request
Insurance coverage	Varies; often requires prior authorization	May be covered; typically lower copay tier
Prescription requirement	Yes; MD, DO, PA, NP authorization mandatory	Yes; same prescriber qualifications required
Side effect profile	Well-established in large clinical trials	Same active ingredient; similar safety profile expected

Clinical Screening and Biomarkers Before Starting GLP-1

Before any GLP-1 initiation—branded or compounded—providers assess kidney function (eGFR), fasting glucose, HbA1c, lipid panel, liver enzymes, calcitonin, and personal/family history of thyroid or pancreatic disease. These biomarkers identify contraindications and guide starting dose, titration pace, and monitoring intervals throughout treatment.

Genetic variation in GLP-1 receptor (GLP1R), glucagon-dependent insulinotropic polypeptide receptor (GIPR), and melanocortin-4 receptor (MC4R) pathways may influence individual metabolic response and side-effect tolerance. The Precision Peptide Genetic Test reveals predispositions in these peptide pathways—information that can support a more personalized provider conversation about expected efficacy and monitoring strategy.

Safety Considerations and Who Should Pursue Prescription Options

GLP-1 medications are appropriate for adults with Type 2 diabetes, prediabetes, or obesity (BMI ≥27 with weight-related conditions or BMI ≥30) under provider supervision. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe pancreatitis, severe kidney disease, or uncontrolled thyroid conditions. Careful evaluation is non-negotiable.

Adverse effects—nausea, vomiting, constipation, abdominal pain, and rare but serious gastrointestinal issues—occur in 20–50% of users depending on titration speed and individual tolerance. Provider-guided dose escalation, dietary adjustments, and ongoing lab monitoring mitigate risk. OTC access would bypass these protections, elevating serious outcomes in vulnerable populations.

How PlexusDx Supports a More Personalized Approach

PlexusDx supports evidence-based, prescription-guided GLP-1 therapy through compounded options and precision assessment. Genetic predispositions in GLP1R, GIPR, and MC4R variants may help contextualize individual metabolic response—information that can support a more informed conversation with your prescriber about starting dose, titration strategy, and realistic efficacy expectations.

The Precision Peptide Genetic Test ($99 as an add-on, $298 standalone) reveals key variants such as GLP1R rs6923761 and MC4R rs17782313. These predispositions in peptide pathways should be interpreted with your qualified healthcare provider—they provide context, not guaranteed outcomes or exact medication response predictions—to tailor your treatment approach.

Whether you choose compounded semaglutide ($179–$229/month), oral semaglutide ($209/month), compounded tirzepatide ($229–$309/month), or our Microdose GLP-1 Protocol ($129/month), pairing your prescription with genetic and biomarker insights may help optimize your metabolic wellness journey under professional supervision.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.